Acute Pain

Reductions in prescribed benzodiazepines were especially noted in continuing prescriptions.

Since the delivery of these medications were disrupted during the pandemic, members of racial and ethnic minority groups experienced an increased risk of opioid overdose, compared with White individuals.

Presence of chronic liver disease, prior use of gabapentin and being discharged to a long-term hospital or rehabilitation center are among some of the factors associated with a new opioid use disorder diagnosis.

A new method of opioid disposal was proposed by the FDA in an attempt to mitigate unauthorized access to opioids and lessen risk of addiction.

Acadia Pharmaceuticals evaluated the effects of its novel redox modulator drug on pain intensity levels of patients undergoing a bunionectomy.

The NaV1.8 inhibitor VX-548 shows promising potential as a non-opioid acute pain treatment.

Mindfulness-oriented recovery enhancement is unlike other mindfulness-based treatments and was found superior to supportive group psychotherapy for treating opioid misuse and chronic pain.

Nearly all of the acupuncture group was fully mobilized on the first postoperative day.

When the pandemic began, prescribers in Canada were allowed to increase the amount of opioid agonist therapy take-home doses for individuals with opioid use disorder.

While recent data indicate the potential to reduce opioid overdose mortality rates with naloxone distribution, authors call for increased support for those who witness an overdose.

Intravenous tramadol, developed by Avenue Therapeutics, fails to attain FDA approval as treatment for acute pain in adults.

A new study highlights the urgency to implement better access and distribution of naloxone to avert witnessed opioid overdose deaths.

The CDC is encouraging public feedback on updated guideline recommendations for opioid prescribers for the first time since 2016.

Experts explain that their analysis clearly lays out how lack of effective regulation and an unchecked profit motive created the opioid epidemic.

The findings of this study can be applied to guide opioid counseling and monitoring when prescribing the medication.

A new study evaluated factors associated with quality of life by observing levels of chronic pain in Chinese patients who were receiving maintenance hemodialysis.

Exposure to long-term prescription opioid therapy was linked to a 3.2-fold higher risk of HCV seroconversion compared to individuals who were prescription opioid-naïve or acute.

Investigators examine the impact that 1 or 2 doses of dexamethasone has on morphine consumption and postoperative pain in patients undergoing a total knee arthroplasty.

Frank Peacock explains how methylnaltrexone can prevent patients with opioid-induced constipation from being hospitalized.

High dose vitamin D supplementation has been linked to fewer pain days and higher physical activity scores for patients with chronic pain.

Investigators found that using virtual reality to reduce pain levels during operational hsyteroscopy was not effective.

EaseVRx utilizes cognitive behavioral therapy and other behavioral therapy techniques.

Dr. Califf formerly led the FDA during the Obama Administration.

The randomized control trial investigates the effectiveness of cognitive behavioral therapy in treating chronic pain in patients who have been using opioid therapy.

New study finds that patients with neuropathic pain may benefit from cannabis-based medicine or medical cannabis.